Clinical Trial Detail

NCT ID NCT02049957
Title Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Millennium Pharmaceuticals, Inc.
Indications

estrogen-receptor positive breast cancer

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Sapanisertib

Exemestane + Sapanisertib

Age Groups: adult

Additional content available in CKB BOOST